Cite
Williams CB, McMahon C, Ali SM, et al. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco Targets Ther. 2015;8:3561-4doi: 10.2147/OTT.S90766.
Williams, C. B., McMahon, C., Ali, S. M., Abramovitz, M., Williams, K. A., Klein, J., McKean, H., Yelensky, R., George, T. J., Elvin, J. A., Soman, S., Lipson, D., Chmielecki, J., Morosini, D., Miller, V. A., Stephens, P. J., Ross, J. S., & Leyland-Jones, B. (2015). A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. OncoTargets and therapy, 83561-4. https://doi.org/10.2147/OTT.S90766
Williams, Casey B, et al. "A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy." OncoTargets and therapy vol. 8 (2015): 3561-4. doi: https://doi.org/10.2147/OTT.S90766
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco Targets Ther. 2015 Dec 01;8:3561-4. doi: 10.2147/OTT.S90766. eCollection 2015. PMID: 26664139; PMCID: PMC4671814.
Copy
Download .nbib